CN1286461C - 含有吗多明的喷雾剂 - Google Patents
含有吗多明的喷雾剂 Download PDFInfo
- Publication number
- CN1286461C CN1286461C CN 200510007729 CN200510007729A CN1286461C CN 1286461 C CN1286461 C CN 1286461C CN 200510007729 CN200510007729 CN 200510007729 CN 200510007729 A CN200510007729 A CN 200510007729A CN 1286461 C CN1286461 C CN 1286461C
- Authority
- CN
- China
- Prior art keywords
- molsidomine
- spray
- medicinal liquid
- medium chain
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 229960004027 molsidomine Drugs 0.000 title claims abstract description 82
- 239000007921 spray Substances 0.000 title claims description 82
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 69
- 239000007788 liquid Substances 0.000 claims abstract description 50
- 239000000194 fatty acid Substances 0.000 claims abstract description 21
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 20
- 229930195729 fatty acid Natural products 0.000 claims abstract description 20
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 20
- 230000000144 pharmacologic effect Effects 0.000 claims abstract description 7
- 229960004756 ethanol Drugs 0.000 claims description 25
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 20
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 14
- 239000000654 additive Substances 0.000 claims description 10
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 1
- 150000005690 diesters Chemical class 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 49
- 238000005507 spraying Methods 0.000 abstract description 27
- 239000008280 blood Substances 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 125000005456 glyceride group Chemical group 0.000 abstract description 4
- 239000000443 aerosol Substances 0.000 description 25
- 229940079593 drug Drugs 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 19
- 239000003826 tablet Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- -1 Morsidomine by name Chemical compound 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 235000019220 whole milk chocolate Nutrition 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- MIJKYXHQIOTHGT-UHFFFAOYSA-N C(C)(C)(C)C=1C(=C(C=CC1)O)C(C)(C)C.CC1=CC=CC=C1 Chemical compound C(C)(C)(C)C=1C(=C(C=CC1)O)C(C)(C)C.CC1=CC=CC=C1 MIJKYXHQIOTHGT-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 2
- 241000640882 Condea Species 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-O N-[3-(4-morpholinyl)-5-oxadiazol-3-iumyl]carbamic acid ethyl ester Chemical compound O1C(NC(=O)OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-O 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006324 decarbonylation Effects 0.000 description 1
- 238000006606 decarbonylation reaction Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000009688 liquid atomisation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
样品 | 喷雾均匀性 | 药液挥发量 | 第1喷量差异 | 最大喷量差异 | 吗多明相对浓度 |
实施例1 | 喷雾均匀,雾滴细小 | 0.61% | 95.4% | 5.4% | 100.2% |
实施例2 | 喷雾均匀,雾滴细小 | -0.24% | 92.8% | 4.2% | 99.8% |
实施例3 | 喷雾均匀,雾滴细小 | -0.89% | 95.9% | 4.9% | 99.7% |
实施例4 | 喷雾均匀,雾滴细小 | 1.03% | 93.7% | 3.3% | 100.4% |
实施例5 | 喷雾均匀,雾滴细小 | -0.57% | 94.4% | 3.8% | 100.1% |
样品 | 喷雾均匀性 | 最大喷量差异 |
0.05ml泵 | 喷雾呈实心锥形,雾滴分布均匀,液滴细小 | 5.4% |
0.10ml泵 | 喷雾呈实心锥形,雾滴分布均匀,液滴细小 | 4.9% |
0.15ml泵 | 喷雾呈实心锥形,雾滴分布均匀,液滴细小 | 5.7% |
样品 | 喷雾剂 | 片剂 | 气雾剂 |
Cmax(ng/ml) | l 8.2 | 15.6 | 18.8 |
Tmax(h) | 0.48 | 0.62 | 0.44 |
AUC0-∞(ng·h/ml) | 66.32 | 64.77 | 66.4l |
t1/2(h) | 1.48 | 1.51 | 1.44 |
t5ng/ml(h) | 4.52 | 3.96 | 4.39 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510007729 CN1286461C (zh) | 2005-02-16 | 2005-02-16 | 含有吗多明的喷雾剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510007729 CN1286461C (zh) | 2005-02-16 | 2005-02-16 | 含有吗多明的喷雾剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1682738A CN1682738A (zh) | 2005-10-19 |
CN1286461C true CN1286461C (zh) | 2006-11-29 |
Family
ID=35262358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510007729 Active CN1286461C (zh) | 2005-02-16 | 2005-02-16 | 含有吗多明的喷雾剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1286461C (zh) |
-
2005
- 2005-02-16 CN CN 200510007729 patent/CN1286461C/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN1682738A (zh) | 2005-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6486124B2 (en) | Cyclosporin compositions and process therefor | |
CN1160079C (zh) | 发泡性肠溶制剂 | |
CN1193792C (zh) | 稳定的口服医药组合物 | |
CN1917859A (zh) | 载药纳米微粒及其制备方法以及含有该纳米微粒的非肠道给药用制剂 | |
CN1531430A (zh) | 含有抗真菌剂的局部用组合物 | |
JPH08505364A (ja) | カルシトニン含有医薬組成物 | |
CN1237106A (zh) | 含有4,5-环氧吗啡喃衍生物的稳定的药物组合物 | |
JP2006501134A (ja) | 高い生物学的利用能を有する、経口活性タキサン誘導体の医薬組成物 | |
JP2006206615A (ja) | 経口投与用シクロスポリン含有新規製剤 | |
US20200345656A1 (en) | Cannabinoids compositions and methods | |
CN1319517C (zh) | 低剂量液体恩替卡韦制剂和用途 | |
WO2020138217A1 (ja) | ワクチンアジュバントを含む製剤 | |
CN1469707A (zh) | 改进的疏水性药物的固体药物剂量制剂 | |
CN1286461C (zh) | 含有吗多明的喷雾剂 | |
CN1083260C (zh) | 用于制备主要活性成分为乙酰水杨酸和灭吐灵的联合体的稳定粉剂的新药物组合物 | |
CN1424105A (zh) | 风油精喷雾剂 | |
CN1732902A (zh) | 含有维生素类物质的喷雾剂 | |
CN1224424C (zh) | 粘膜吸附性的热凝性医药载体组合物 | |
JP3048602B2 (ja) | ポリプレニル系化合物を含有する医薬組成物およびその製造方法 | |
CN1263736C (zh) | 四水合n-[邻-(对-三甲基乙酰氧基苯磺酰胺基)苯甲酰基]甘氨酸单钠盐的溶液及其药品 | |
CN100335050C (zh) | 水飞蓟宾的药物组合物 | |
CN1053547A (zh) | 药物制剂 | |
CN1732908A (zh) | 含有冰片的喷雾剂 | |
CN1160128C (zh) | 含有丙二醇和异丙基链烷酸酯的抗病毒制剂 | |
CN1698621A (zh) | 非那雄胺高浓度溶液及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090320 Address after: Jinxi road Binhu District of Jiangsu city of Wuxi province No. 100 Patentee after: Xu Xiaochun Address before: Room 702, building 3, building 3, building two, Beijing Town, Xiyuan District, Changping District Patentee before: Yan Siping |
|
ASS | Succession or assignment of patent right |
Owner name: XU XIAOCHUN Free format text: FORMER OWNER: YAN SIPING Effective date: 20090320 |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Xu Xiaochun Document name: Notification of Passing Examination on Formalities |
|
ASS | Succession or assignment of patent right |
Owner name: WUXI BOYA BIOENGINEERING CO., LTD. Free format text: FORMER OWNER: XU XIAOCHUN Effective date: 20100824 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 214081 NO. 100, JINXI ROAD, BINHU DISTRICT, WUXI CITY, JIANGSU PROVINCE TO:214092 NO. 88, MASHANMEILIANG ROAD, BINHU DISTRICT, WUXI CITY, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100824 Address after: Ma Shan Mei Binhu District 214092 in Jiangsu province Wuxi City Road No. 88 beam Patentee after: Wuxi Boya Bio-technology Co.,Ltd. Address before: Jinxi road Binhu District 214081 Jiangsu city of Wuxi province No. 100 Patentee before: Xu Xiaochun |
|
C56 | Change in the name or address of the patentee |
Owner name: BOYALIFE STEM CELL TECHNOLOGY CO., LTD. Free format text: FORMER NAME: WUXI BOYALIFE BIOENGINEERING CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Ma Shan Mei Binhu District 214092 in Jiangsu province Wuxi City Road No. 88 beam Patentee after: Boya Stem Cell Technology Co., Ltd. Address before: Ma Shan Mei Binhu District 214092 in Jiangsu province Wuxi City Road No. 88 beam Patentee before: Wuxi Boya Bio-technology Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: YINGKE BOYA GROUP CO., LTD. Free format text: FORMER OWNER: BOYA STEM CELLS TECHNOLOGY CO., LTD. Effective date: 20150529 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150529 Address after: 214092 No. 800 Jiefang East Road, Nanchang District, Jiangsu, Wuxi Patentee after: Intco Boya Group Co. Ltd. Address before: Ma Shan Mei Binhu District 214092 in Jiangsu province Wuxi City Road No. 88 beam Patentee before: Boya Stem Cell Technology Co., Ltd. |